Join Growin Stock Community!

Evaxion biotech a/sEVAX.US Overview

US StockHealthcare
(No presentation for EVAX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

EVAX AI Insights

EVAX Overall Performance

EVAX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EVAX Recent Performance

-

Evaxion biotech a/s

0.05%

Avg of Sector

-0.31%

S&P500

EVAX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

EVAX Key Information

EVAX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

EVAX Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Price of EVAX

EVAX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EVAX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.86
PE Ratio (TTM)
-
Forward PE
4.58
PS Ratio (TTM)
3.45
PB Ratio
8.51
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-70.87%
Revenue Growth (YoY)
132.16%
Profit Growth (YoY)
132.16%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.86
PE Ratio (TTM)
-
Forward PE
4.58
PS Ratio (TTM)
3.45
PB Ratio
8.51
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-70.87%
Revenue Growth (YoY)
132.16%
Profit Growth (YoY)
132.16%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is EVAX's latest earnings report released?

    The most recent financial report for Evaxion biotech a/s (EVAX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EVAX's short-term business performance and financial health. For the latest updates on EVAX's earnings releases, visit this page regularly.

  • What is the operating profit of EVAX?

    According to the latest financial report, Evaxion biotech a/s (EVAX) reported an Operating Profit of 3.02M with an Operating Margin of 40.34% this period, representing a growth of 274.58% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is EVAX's revenue growth?

    In the latest financial report, Evaxion biotech a/s (EVAX) announced revenue of 7.49M, with a Year-Over-Year growth rate of 148.33%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does EVAX have?

    At the end of the period, Evaxion biotech a/s (EVAX) held Total Cash and Cash Equivalents of 10.57M, accounting for 0.36 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does EVAX go with three margins increasing?

    In the latest report, Evaxion biotech a/s (EVAX) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -11,729.73%%, and net margin of -13,056.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess EVAX's profit trajectory and future growth potential.

  • Is EVAX's EPS continuing to grow?

    According to the past four quarterly reports, Evaxion biotech a/s (EVAX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 4.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What are the PEG ratio and PE ratio of EVAX?

    The latest valuation data shows Evaxion biotech a/s (EVAX) has a Price-To-Earnings (PE) ratio of -1.51 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.